Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
T-326 Inhaler · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| T-326 | EXPERIMENTAL | Non Cystic fibrosis bronchiectasis patients will be enrolled for determination of peak inspiratory flow. |
| Name | Type | Description |
|---|---|---|
| T-326 Inhaler | DEVICE | No drug dosing,three test inhalations through the inhaler device filled with an empty capsule. |
Inclusion Criteria: * Established diagnosis of non-cystic fibrosis bronchiectasis, confirmed and documented by high resolution computed tomography (HRCT) or magnetic resonance tomography (MRT) * Ability to reproducibly perform spirometry according to American Thoracic Society/European Respiratory S...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AstraZeneca PLC | AZN | 2 | PHASE2 | AZD0292 |
| GSK plc Sponsored ADR | GSK | 1 | PHASE2 | GSK3862995B |
| Merck & Co., Inc. | MRK | 1 | PHASE2 | Nebulized Ensifentrine |
| Baxter International Inc. | BAX | 1 | N/A | Undisclosed |
| Inogen, Inc. | INGN | 1 | N/A | Undisclosed |
T-326 Inhaler is an investigational drug being developed for the treatment of bronchiectasis, a respiratory condition. It is currently in Phase 1 clinical development. The drug is administered via inhalation, and its exact mechanism of action has not been disclosed.
T-326 Inhaler is being developed by Bayer AG, a multinational pharmaceutical company. Bayer's stock is traded under the ticker symbol BAYRY on the OTC market. The drug is in Phase 1 clinical development for bronchiectasis.
T-326 Inhaler is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The drug is being studied for the treatment of bronchiectasis, a chronic respiratory condition.
T-326 Inhaler has one completed Phase 1 clinical trial, identified by the NCT number NCT02563197. This trial, titled "Inhalation Flow Rate-study," was conducted in Germany and enrolled 33 participants with bronchiectasis. The trial was not randomized, double-blind, or controlled.
T-326 Inhaler is not FDA approved. It is an investigational drug currently in Phase 1 clinical development for bronchiectasis. The drug has not yet completed the clinical trials required for regulatory approval, and its safety and efficacy have not been established.